Series Parts

NMN and Nicotinamide Riboside: What the Trials Actually Show

Oral NMN and NR reliably raise circulating NAD+ in humans. Effects on metabolic, muscle, vascular, and cognitive outcomes are mixed and often modest or absent. The gap between biomarker and benefit is the central fact.

Todd Ruffner-Schoenfeld Editor in chief. A knack for the fine print, and likes it. 15 Aug 2026 4 min read 5 sources E.G. v4.16

A mass of golden supplement capsules — Supplement capsules of the kind sold for NAD+ support. CC0 photograph (Oddman47), via Wikimedia Commons.

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are the two precursors that have dominated both the research literature and the commercial market for NAD+ augmentation. Both can be taken orally. Both feed into the cellular pathways that synthesize NAD+. And both have been tested in multiple human trials.

A clear pattern has emerged from those trials and from systematic reviews of them. Target engagement is real. Clinical efficacy for anti-aging or broad wellness outcomes remains inconclusive.

Reliable Target Engagement

Across randomized and non-randomized studies, oral NR and NMN consistently increase NAD+-related metabolites in blood. Dose-dependent rises have been documented. In head-to-head work, a 2026 head-to-head trial in sixty-five adults showed that both NMN and NR roughly doubled circulating NAD+ after two weeks of daily gram-level dosing, while a lower dose of nicotinamide produced only a transient rise.

Illustration of two vials, the second twice as bright — Two weeks of gram-level NMN or NR roughly doubles circulating NAD+. AI-generated illustration.

These findings confirm that the precursors are bioavailable in humans and that they engage the intended biochemical pathway. Safety and tolerability in trials lasting weeks to a few months have generally been favorable, with few serious adverse events attributed to the supplements at the doses studied.

That biochemical success is the foundation of the commercial case. It is also where the stronger claims often stop being supported by the data.

Functional and Clinical Outcomes

Systematic reviews of human intervention studies paint a more cautious picture once the focus moves beyond NAD+ levels. Effects on metabolic parameters such as insulin sensitivity, glucose control, and lipid profiles have been heterogeneous. Some trials report modest benefits in specific subgroups or at particular doses; many report null results on primary metabolic endpoints.

Muscle-related outcomes have been similarly mixed. Meta-analyses examining skeletal muscle mass, strength, and function in older adults have not found consistent significant benefits of NMN or NR on measures such as handgrip strength, gait speed, or muscle mass indices. Isolated positive signals exist in certain populations or secondary endpoints, but the overall evidence does not support a reliable effect on sarcopenia-related measures.

Illustration of a human figure unchanged while energy particles rise around it — The measured strength, gait, and muscle mass largely did not move with the biomarker. AI-generated illustration.

Vascular and blood-pressure findings are likewise modest. Some analyses suggest small reductions in diastolic blood pressure; effects on systolic pressure have been less consistent and may be more apparent in older subgroups. Cognitive outcomes remain limited. A 2026 phase-two trial in amnestic mild cognitive impairment roughly doubled blood NAD+ and increased left hippocampal blood flow, without a statistically significant improvement in memory over the study period. It is worth reading alongside the broader picture of cellular energy and aging.

A 2026 PRISMA-guided systematic review of NAD+-related interventions concluded that oral NR and NMN demonstrate clear biochemical target engagement and are generally well tolerated, yet effects on functional, metabolic, vascular, and other healthspan-relevant outcomes are heterogeneous and often null or endpoint-specific. The review also found that direct evidence for infused NAD+, given intravenously or intramuscularly for anti-aging or wellness, is notably thin.

Regulatory Context for NMN

NMN occupied an unusual regulatory position for several years. In 2022 the FDA took the view that NMN was excluded from the dietary supplement definition, because it had been authorized for investigation as a new drug and substantial clinical investigations had been made public. That position limited lawful marketing of NMN as a supplement in the United States for a period.

In September 2025, following citizen petitions and further review, the agency reversed that position, concluding NMN had been marketed as a dietary supplement before the relevant drug authorization and so was not excluded. As of late 2025, NMN may again be used in dietary supplements, though it remains a new dietary ingredient that still requires a notification to the FDA rather than a fully cleared one. The episode illustrates how regulatory status, commercial availability, and scientific evidence can move on different timelines.

How Commercial Claims Are Built

Product marketing typically emphasizes the reliable rise in NAD+ and then extrapolates to energy, recovery, metabolic health, cognitive support, or healthy aging. The extrapolation step is where the evidence thins. Raising a circulating biomarker is not the same as demonstrating that the downstream physiology of aging has been altered in a clinically meaningful way.

Some commercial content cites individual positive trials while giving less weight to null results or to the systematic reviews that integrate both. Dose, duration, population, and endpoint selection all influence whether a given trial finds an effect. Averaging across the literature produces a more tempered conclusion than any single optimistic study.

What Remains Open

Several questions are still active. Optimal dosing and duration for any specific outcome are not settled. Whether certain subgroups, older adults with clear NAD+ deficits, people with particular metabolic diseases, or those under defined physiological stress, derive more benefit is plausible but not fully mapped. Combinations with other interventions (exercise, dietary pattern, other compounds) may produce different results than precursors alone. Long-term safety and efficacy data beyond several months remain limited.

These open questions are normal for an active research field. They are less convenient for a marketplace that prefers definitive claims. The responsible reading of the current evidence is that NMN and NR do what they are biochemically expected to do in blood, that they appear safe in the short to medium term at studied doses, and that proof of broad, reliable clinical benefit for aging-related outcomes has not yet been established at the level required for strong recommendations.

Sources

Built against current standards generation: E.G. v4.16 · I.R.G. v1.13 · L.R.G. v1.9 · P.L.G. v1.10 · SEO G. v1.5 · Publishing Checklist v1.3. As of August 2026.

Written by Todd Ruffner-Schoenfeld Editor in chief. A knack for the fine print, and likes it.

Todd Ruffner-Schoenfeld has spent his working life being handed things he did not yet understand. He started at the bottom, a developer in a bullpen, and worked his way up to running IT. The places were a strange assortment: consulting firms, accounting firms, a biotech startup, a tech startup in Silicon Valley and, of all places, Chiquita. Four small businesses of his own along the way. The work never really changed. Get into something unfamiliar, find out what is actually going on, and help someone make a hard decision with it. HeadLines Decoded is that job, pointed at the news.